Cantó, E, del Prado, ME, Vilarrasa, E, López-Ferrer, A, de Aranibar, FJGL, Ortiz, MA, Gut, M, Mulet, M, Esteve-Codina, A, Osuna-Gómez, R, Guinart-Cuadra, A, Puig, L, Vidal, S. Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(17)DOI:10.3390/ijms26178118. PMID:40943056. IF:4.900(Q1/3D).

Salgado-Boquete, L, Puig, L, Carrascosa, JM, de la Cueva, P, Ferrer, AL. Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis. Actas Dermo-Sifiliograficas. 2025; 116(7)DOI:10.1016/j.ad.2025.05.011. PMID:40446921. IF:(Q/D).

Dobao, PD, Barredo, LC, Salvador, JFS, Serra-Baldrich, E, Pinto, PH, Cano, NH, De Frutos, FJO, Gullón, GR, Belloso, RML, Ortega, IA, Quesada, AG, Gutiérrez, MG, Calzada, YG, Torredemer, DA, Felius, NL, Martin, IH, Laserna, FJR. Patient Burden and Impact of Moderate-to-Severe Atopic Dermatitis in the Spanish Healthcare System: The APOLO Cross-Sectional Study. Dermatology Practical & Conceptual. 2025; 15(3)DOI:10.5826/dpc.1503a5538. PMID:40790435. IF:2.300(Q2/5D).

Cheon, JH, Ye, BD, Armuzzi, A, Rieder, F, Girolomoni, G, Puig, L, Jung, HJ, Feldman, SR. The 'totality of evidence' and 'extrapolation' of SB17, a ustekinumab biosimilar. EXPERT OPINION ON BIOLOGICAL THERAPY. 2025; 25(6)DOI:10.1080/14712598.2025.2508838. PMID:40396611. IF:4.000(Q2/3D).